PT  - JOURNAL ARTICLE
AU  - Tabrizi, Reza
AU  - Lankarani, Kamran B
AU  - Nowrouzi-sohrabi, Peyman
AU  - Shabani-Borujeni, Mojtaba
AU  - Rezaei, Shahla
AU  - Hosseini-bensenjan, Mahnaz
AU  - vakili, Sina
AU  - Heydari, Seyed Taghi
AU  - Ashraf, Mohammad Ali
TI  - The role of comorbidities and clinical predictors of severe disease in COVID-19: a systematic review and meta-analysis
AID  - 10.1101/2020.04.21.20074633
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.21.20074633
4099  - http://medrxiv.org/content/early/2020/04/25/2020.04.21.20074633.short
4100  - http://medrxiv.org/content/early/2020/04/25/2020.04.21.20074633.full
AB  - Background COVID_19 is unpredictable due to non-specific symptoms and clinical course diversity in different individuals. We analyzed studies regarding the factors associated with severe status of the disease to identify unique findings in severely affected patients.Methods We systematically searched the electronic databases, including PubMed, Scopus, EMBASE, Web of Science, and Google Scholar from inception to 12th of March 2020. Cochrane’s Q and I-square statistics were used to assess the existence of heterogeneity between the included studies. We used the random-effects model to pool the odds ratios (ORs) at 95% confidence intervals (CIs).Results Seventeen articles out of 3009 citations were included. These contained 3189 patients, of whom 732 were severely affected (severe group) and 3189 were in non-severe group. Using the random-effects model, our meta-analyses showed that the odds of comorbidities, including COPD, DM, HTN, CVD, CKD, and symptoms, including dyspnea, dizziness, anorexia, and cough, were significantly higher among the severe group compared with the non-severe group. There were no significant changes in odds of CVA, liver disease, immunodeficiency/immunosuppression, fever, fatigue, myalgia, headache, diarrhea, sore throat, nasal congestion, sputum, nausea, vomiting, chest pain between the two groups.Conclusions Early recognition and intervention can be critical in management, and might stop progression to severe disease. Predictive symptoms and comorbidities can be used as a predictor in patients who are at risk of severe disease.Competing Interest StatementThe authors have declared no competing interest.Funding Statementthis project was not funded by any organization.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata regarding the manuscript will be available as request